Parkinson's Disease Flashcards

1
Q

Describe the prevalence, age of onset and gender bias of parkinon’s disease

A

2nd most common ND disease
80,000 Aus (1/350), 8-10 million worldwide
57yrs avg age onset
men 1.5x more likely

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the cardinal symptoms of PD

A

tremor at rest
rigidity
akinesia (loss mvm)
bradykinesia
postural instability/gait change
must have at least 2, including resting tremor or bradykinesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are some non-motor symptom categories of PD

A

personality and behaviour
cognition and mental
sensory
autonomic
sleep problems
fatigue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

describe cognitive impairment in parkinson’s

A

range from mild cognitive impairment -> dementia
25% have cognitive impairment
80% develop parkinson’s disease dementia within 20 years diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

diagnosis of parkinson’s disease

A

no definitive test
clinical symptoms, ruling our other disorders, levadopa
neuroimaging can look at dopamine uptake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

course of parkinsons disease progression

A

symptoms can begin insiduously and gradually worsen
avg survival time = 12 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

early warning signs of PD

A

loss of smell
REM sleep behavioural disorder
neuropsychiatric changes
GI changes
by the time you get motor symptoms, already lost 60% dopaminergic neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the etioogly of PD

A

familial PD = 5-10%
idiopathic PD: 90-95% (environmental = gene combo probably, env= history TBI, pesticide/herbicide exposure)
tea + coffee antioxidants (caffeine and theobromine = adenosine antagonists) cam improve PD symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe the basal ganglia

A

group of nuclei deep within the brain
voluntary motor control, procedural learning, eye mvm, cognitive an emotional function
caudata nucleus, putamen (striatum) globus pallidus, subthalamic nucleus, substantia nigra (where degeneration starts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

role of basal ganglia in mvm

A

gating proper initiation of mvm -> motor cortex
fine motor control
inhibition of what you don’t need, excitation of what you do need

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

summarise the circuitry of the basal ganglia

A

direct pathway promotes execution of planned motor action by exciting cortical neurons
indirect inhibits motor action by inhib cortical neurons
pathways balanced or smooth execution of mvm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe the circuitry of the direct pathway

A

cerebral cortex -> planning mvm sends excitatory signal via glut -> striatum -> secretion of dopamine binds to D1 GABA-yn receptors in the striatum -> inc inhibition (GABA release) on the globus pallidus interna/substantia nigra reticulata (inhibits these inhibitors) => reduce inhibition on thalamus to increase glutamate excitation on cortex rom thalamus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

describe the circuitry of the indirect pathway

A

substantia nigra -> dopamine binds to D2 GABA-3nk receptors -> reduce inhibition on globus pallidus externa (normally inhibits subthalamic nucleus) -> excites globus pallidus interna/substantia nigra reticula -> more inhibition of thalamus -> less excitation from thalamus to cortex -> reduces motor mvm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

effect of globus pallidus interna/substantia nigra reticula

A

decrease the effect of the thalamus to decrease excitation of the cortex
so direct pathway must inhibit these inhibitors to cause thalamus excitation
and the indirect pathway must excite the inhibitors to cause thalamus inhibition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

whats the balance between the direct and indirect pathways in PD

A

severe loss dopamine in SNc, hypokinetic
reduced execution of mvm means that direct pathway is more affected
increased inhibition of mvm for indirect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what happens when dopamine is lost

A

output nuclei become overactive (Gpe, SNr)
no dopamine = unchecked effects of cortical input => basal ganglia = imbalanced
output nuclei over inhibit thalamus (normally excitatory relays to cerebral cortex)
also oscillatory neuronal discharge (tremor) + altered output to brainstem (rigidity)

17
Q

describe the degeneration of other neuronal populations in PD

A

noradrenaline neurons in locus coeruleus (motor, depression, adhd)
ACH neurons in nucles basalis of meynery (plasticity, arousal, memory)
serotonin (5-HT) neurons of the dorsal raphe nucleus (regulation of mood, appetite, sleep muscle contraction)

18
Q

what are lewy bodies ad why do they suck

A

pathological hallmark of PD
protein, alpha-synuclein abnormally deposits, leading to formation intracellular lewy bodies (core + halo)
secreted by damaged neurons and can be taken up by surrounding neurons + structures (like microglia)
spreads in ascending direction

19
Q

describe the Braak stages

A

1+2 => autonomic and olfactory disturbance (olfactory bulb, vagus nerve => premotor symptoms)
3+4 => sleep and motor disturbances (motor symptoms)
5+6 => emotional and cognitive disturbances

20
Q

describe the braak staging of lewy bodies

A

spread of lewy bodies from lower brainstem up to cortex
parallels clinical progression of the disease

21
Q

describe pathological transmission of a-synuclein

A

EC space -> taken up by health neurons, causing normal a-syn to misfold -> secretes damaged a-syn

22
Q

prion-like hypothesis

A

a-syn spread along anatomical regions similar manner to prion proteins in prion disease (Creutzfeldt-Jacob)

23
Q

treatments of PD

A

no cure
treatments slow down progression + symptoms
levadopa

24
Q

details about levadopa

A

prodrug = metabolic precursor of dopamine
levadopa cross BBB (dopamine cant)
enzymatically converted to dopamnie in CNS
1-3% enters brain bc extracerebral metabolism = reduced by coupling with dopa-decarboxylase inhibitor to prevent peripheral conversion of dopamine

25
Q

effectiveness of levadopa

A

best results in first few years
80% = improvement
20% virtually normal motor function
levadopa therapy = less effective over time
progressive loss of dopaminergic neurons